Wyant T - Search Results

1

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.

Wyant T, Yang L, Fedyk E. Wyant T, et al. MAbs. 2013 Nov-Dec;5(6):842-50. doi: 10.4161/mabs.26392. MAbs. 2013. PMID: 24492340 Free PMC article.

2

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. Soler D, et al. Among authors: wyant t. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9. J Pharmacol Exp Ther. 2009. PMID: 19509315

3

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ. Fedyk ER, et al. Among authors: wyant t. Inflamm Bowel Dis. 2012 Nov;18(11):2107-19. doi: 10.1002/ibd.22940. Epub 2012 Mar 14. Inflamm Bowel Dis. 2012. PMID: 22419649

4

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.

Wyant T, Estevam J, Yang L, Rosario M. Wyant T, et al. Cytometry B Clin Cytom. 2016 Mar;90(2):168-76. doi: 10.1002/cyto.b.21236. Epub 2015 Apr 27. Cytometry B Clin Cytom. 2016. PMID: 25908521 Free article. Clinical Trial.

5

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

Wyant T, Fedyk E, Abhyankar B. Wyant T, et al. J Crohns Colitis. 2016 Dec;10(12):1437-1444. doi: 10.1093/ecco-jcc/jjw092. Epub 2016 Jun 1. J Crohns Colitis. 2016. PMID: 27252400 Review.

6

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.

Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. Rosario M, et al. Among authors: wyant t. Clin Pharmacokinet. 2017 Nov;56(11):1287-1301. doi: 10.1007/s40262-017-0546-0. Clin Pharmacokinet. 2017. PMID: 28523450 Free PMC article. Review.

7

Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.

Wyant T, Yang L, Rosario M. Wyant T, et al. AAPS J. 2020 Nov 16;23(1):3. doi: 10.1208/s12248-020-00518-0. AAPS J. 2020. PMID: 33200296 Free PMC article.

8

Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.

Wyant T, Yang L, Lirio RA, Rosario M. Wyant T, et al. J Clin Pharmacol. 2021 Sep;61(9):1174-1181. doi: 10.1002/jcph.1877. Epub 2021 Jul 14. J Clin Pharmacol. 2021. PMID: 33908636 Free PMC article.

9

Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.

Haanstra KG, Hofman SO, Lopes Estêvão DM, Blezer EL, Bauer J, Yang LL, Wyant T, Csizmadia V, 't Hart BA, Fedyk ER. Haanstra KG, et al. Among authors: wyant t, t hart ba. J Immunol. 2013 Mar 1;190(5):1961-73. doi: 10.4049/jimmunol.1202490. Epub 2013 Jan 30. J Immunol. 2013. PMID: 23365083

10

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.

Song S, Yang L, Trepicchio WL, Wyant T. Song S, et al. Among authors: wyant t. J Immunol Res. 2016;2016:3072586. doi: 10.1155/2016/3072586. Epub 2016 May 31. J Immunol Res. 2016. PMID: 27340678 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters